Lobular Carcinoma

This is a type of breast cancer. The cancer cells grow in the milk-producing glands (lobules) of the breast. It's one of the main types of breast cancer.

Condition

What people with Lobular Carcinoma report

Every report comes from a Lived member, sent anonymously.

Have you had Lumpectomy for Lobular Carcinoma?

NameHow it went

About Lobular Carcinoma

What It Is

Lobular carcinoma, usually called invasive lobular carcinoma (ILC), is a type of breast cancer that starts in the lobules, the small glands in the breast that make milk. It is the second most common type of invasive breast cancer, making up about 10 to 15 percent of cases. Invasive means the cancer cells have grown out of the lobule into the surrounding breast tissue, from where they can spread to lymph nodes and other parts of the body. What sets ILC apart is the way it grows. Its cells lose a protein called E-cadherin that normally holds cells together, so instead of forming a firm, round lump they spread through the breast in thin, single-file strands. ILC therefore often shows up as a vague area of thickening or fullness rather than a distinct lump, and it can be harder to feel during an exam or to see on a mammogram. It is also more likely than other breast cancers to affect both breasts. Lobular carcinoma in situ (LCIS) has a similar name but is a different condition. In LCIS, abnormal cells stay inside the lobules without invading. It is not considered cancer. It signals a higher chance of developing breast cancer later, in either breast, and usually leads to closer screening rather than cancer treatment.

Causes & Risk Factors

Like other breast cancers, ILC develops from changes in the DNA of breast cells, and for most people no single cause can be identified. Risk rises with age, and ILC tends to be diagnosed somewhat later in life than the more common ductal type. Most lobular cancers grow in response to the hormone estrogen, which helps explain why hormone exposure matters: across many studies, lobular cancer is the type of breast cancer most strongly linked to menopausal hormone therapy, particularly combined estrogen and progestin. General breast cancer risk factors, such as dense breast tissue, alcohol use and a previous diagnosis of LCIS, also apply. A small share of lobular cancers, around 4 to 5 percent, are linked to an inherited change in the CDH1 gene, the gene that makes E-cadherin. The same inherited change raises the risk of a form of stomach cancer called diffuse gastric cancer. For that reason, genetic counseling is worth discussing for people diagnosed with lobular cancer at a young age, in both breasts, or with a strong family history of breast or stomach cancer. These are risk factors, not causes in any one person, and having them does not mean someone brought the cancer on themselves.

How It's Diagnosed

ILC may first be suspected from a screening mammogram or from a change someone notices, such as an area of thickening or hardness, a change in breast size or shape, dimpled skin, or a nipple that has turned inward. Because ILC spreads in strands rather than forming a dense mass, a mammogram or ultrasound can miss it or underestimate how large it is. The diagnosis is made with a biopsy, usually a needle sample of tissue examined by a pathologist, who identifies the lobular pattern under the microscope. The same tissue is tested for hormone receptors (whether the cells respond to estrogen or progesterone) and for HER2, a protein that drives some breast cancers. Most ILCs are hormone receptor positive and HER2 negative, and these results guide treatment more than the lobular label does. Because standard imaging tends to underestimate ILC, a breast MRI may be recommended before surgery to map how far the cancer extends and to check the other breast. In one large study of people with ILC, those who had an MRI before surgery were much less likely to need a second operation. Staging then brings together the tumor's size, whether lymph nodes are involved and whether the cancer has spread elsewhere, which determines what further tests and treatment are needed.

Treatment Options

ILC is treated in largely the same way as other invasive breast cancers, guided mainly by its stage and by the hormone receptor and HER2 results. Most people have surgery. Breast-conserving surgery (lumpectomy, which removes the tumor with a rim of healthy tissue, followed by radiation) controls lobular cancer about as well as it controls other types when it is a suitable option. Because ILC's edges are hard to see, the first operation more often leaves cancer cells at the edge of the removed tissue, so a second operation is more common. Some people choose or need a mastectomy, removal of the whole breast. The lymph nodes in the armpit are checked, usually by removing only the first few nodes the cancer would reach (a sentinel lymph node biopsy). Removing many lymph nodes raises the chance of lymphedema, a lasting swelling of the arm, and of shoulder stiffness. Hormone therapy is the backbone of treatment for most people with ILC, because most lobular cancers depend on estrogen to grow. Tamoxifen blocks estrogen from acting on cancer cells and is used mainly before menopause. Aromatase inhibitors, such as letrozole (Femara) and anastrozole (Arimidex), lower the amount of estrogen the body makes; they are used after menopause, or before menopause together with treatment that switches off the ovaries. These daily pills are usually taken for at least 5 years, and sometimes up to 10, to lower the chance of the cancer coming back. Hot flashes are common with both; aromatase inhibitors often cause joint aches and gradual bone thinning, which is checked with bone density scans. For people at higher risk of recurrence, a targeted drug called a CDK4/6 inhibitor, such as abemaciclib (Verzenio) or ribociclib (Kisqali), may be added for the first 2 or 3 years. Chemotherapy plays a smaller role than in many other breast cancers. Classic ILC tends to grow slowly and responds poorly to chemotherapy, and studies of early-stage ILC have not shown a clear survival benefit for most people. It is still considered for higher-risk cancers, such as pleomorphic lobular carcinoma (a faster-growing variant), tumors that are HER2 positive or lack hormone receptors, or cancers involving several lymph nodes. If ILC has spread to other parts of the body, treatment usually combines hormone therapy with targeted drugs and aims to control the cancer and its symptoms for as long as possible.

What to Expect

As with other breast cancers, the outlook depends mainly on the stage at diagnosis and the cancer's features, and many people with early-stage ILC are treated with the aim of cure. Treatment usually unfolds over months: surgery and recovery, several weeks of radiation if it is part of the plan, sometimes chemotherapy, and then years of daily hormone pills. The long hormone therapy phase is where many people feel the treatment most. Hot flashes, joint aches and fatigue can wear on daily life, and they are worth raising with the care team rather than enduring, since switching medicines or treating the symptoms often makes it possible to complete the full course. Follow-up visits are usually every 3 to 6 months at first, becoming about yearly after 5 years, with yearly mammograms of any remaining breast tissue. Routine scans and blood tests are not usually needed when someone feels well. A distinctive feature of ILC is that it can come back late, sometimes more than 10 years after diagnosis. When it spreads, it more often involves the bones and less common places such as the digestive tract, the ovaries or the lining of the abdomen, where early symptoms can be vague. That is why long-term follow-up continues well after active treatment ends, and why new, lasting symptoms deserve attention even years later.

When to Seek Help

Arrange a breast evaluation for a new area of thickening or hardness, a change in breast size or shape, dimpled or puckered skin, or a nipple that has turned inward, even if a recent mammogram was normal, since mammograms can miss lobular cancer. If you have been treated for ILC, contact your care team promptly rather than waiting for the next scheduled visit if you develop new symptoms that do not settle, including ones that seem unrelated to the breast, such as persistent bone pain or ongoing abdominal discomfort or bloating. Also call about new swelling in the arm on the treated side, or side effects that make it hard to keep taking hormone therapy.

Questions to Ask Your Doctor

  1. 1.Does the lobular type change which surgery or imaging makes sense for me, and would an MRI before surgery be helpful?
  2. 2.What do my hormone receptor and HER2 results mean for my treatment, and how likely is chemotherapy to add benefit in my situation?
  3. 3.How long will I take hormone therapy, and what are our options if its side effects become hard to live with?
  4. 4.Given my age and family history, should I have genetic counseling or testing, including for the CDH1 gene?
  5. 5.What will my follow-up look like over the long term, and which symptoms should prompt me to call between visits?

Last reviewed • Oct 2026

Educational content, not medical advice.